Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Resalis Therapeutics

Request full access

Biopharma company focused on the development of oligonucleotide anti-sense therapies to treat metabolic disorders, including NAFLD/MAFLD/NASH, obesity, and cancer

Turin, ItalyFounded 2021Biotech & Life Sciences

About Resalis Therapeutics

Resalis Therapeutics is a biotechnology startup that operates in the healthcare sector, specifically focusing on the development of treatments for metabolic diseases such as obesity and fatty liver disease. The company's innovative approach targets a master regulator of multiple pathways that underlie these diseases, using a non-coding RNA drug modality. In simpler terms, they are developing drugs that can interact with our genetic material to regulate the body's metabolism and combat these diseases.

Their lead program, RES-010, is being developed as a safe and convenient treatment that not only aids in weight loss but also reduces hepatic steatosis, a condition characterized by the buildup of fat in the liver. The company's business model revolves around the research, development, and eventual commercialization of this drug. They aim to generate revenue through the sale of RES-010 once it has been approved for use in the market.

Resalis Therapeutics serves a broad client base that includes individuals suffering from obesity and fatty liver disease. Given the increasing prevalence of these conditions globally, the market potential for their product is significant. The company is currently in the preclinical stage, gathering robust evidence to support the effectiveness of RES-010. They plan to rapidly progress to clinical trials, testing the drug on a range of metabolic disorders.

Source: Dealroom company data

At a glance

Status
Operational
Employees
12
Open positions
None listed
Dealroom signal
74.0/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotechnology, Weight Management, Spinout, Metabolism, Longevity, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B

Funding history

5 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
EARLY VC✓Equity / VC Oct 2024 $0 — Sanofi Ventures ↗
SERIES A✓Equity / VC Jan 2024 $11M $44M Claris Ventures · Sunstone Life Science Ventures ↗
Showing the latest 2 of 5 recorded eventsBook a demo for the full funding history →

Growth signals

Resalis Therapeutics website traffic

Latest recorded traffic for Resalis Therapeutics is 310 monthly website visits, up 210% over the last three months. Resalis Therapeutics's team grew 0% over the past year.

Latest monthly visits310 3-month web change+210% 1-year team growth0%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Resalis Therapeutics in the Turin ecosystem

Live from Dealroom

The Resalis Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

7 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed3 investors entered at this stage

Series A2 investors entered at this stage

  • Sunstone Life Science Ventures
  • Sanofi Ventures

Other known investors2 additional known investors

  • Aalborg University
  • Silvia Pugi
Team profiled 8 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 2 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
4 countries with
team presence
🇮🇹 Italy70%
🇺🇸 United States10%
🇩🇰 Denmark10%
🇩🇪 Germany10%
4 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Resalis Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Resalis Therapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.